Ryan P Merkow1, Karl Y Bilimoria, James S Tomlinson, Jennifer L Paruch, Jason B Fleming, Mark S Talamonti, Clifford Y Ko, David J Bentrem. 1. *Division of Research and Optimal Patient Care, American College of Surgeons, Chicago, IL; †Surgical Outcomes and Quality Improvement Center and the Northwestern Institute for Comparative Effectiveness Research (NICER) in Oncology, Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL; ‡Department of Surgery, University of Chicago Pritzker School of Medicine, Chicago, IL; §Department of Surgery, University of California, Los Angeles and VA Greater Los Angeles Healthcare System, Los Angeles, CA; ¶Department of Surgical Oncology, MD Anderson Cancer Center, Houston, TX; ‖Department of Surgery, Northshore University Health System, Evanston, IL; and **Department of Surgery, Jesse Brown Veteran Affairs Medical Center, Chicago, IL.
Abstract
OBJECTIVE: To assess the impact of postoperative complications on the receipt of adjuvant chemotherapy. BACKGROUND: Randomized trials have demonstrated that adjuvant chemotherapy is associated with improved long-term survival. However, pancreatic surgery is associated with significant morbidity and the degree to which complications limit subsequent treatment options is unknown. METHODS: Patients from the American College of Surgeons National Surgical Quality Improvement Program and the National Cancer Data Base who underwent pancreatic resection for cancer were linked (2006-2009). The associations between complications and adjuvant chemotherapy use or treatment delay (≥ 70 days from surgery) were assessed using multivariable regression methods. RESULTS: From 149 hospitals, 2047 patients underwent resection for stage I-III pancreatic adenocarcinoma of which 23.2% had at least 1 serious complication. Overall adjuvant chemotherapy receipt was 57.7%: 61.8% among patients not experiencing any complication and 43.6% among those who had a serious complication. Serious complications increased the likelihood of not receiving adjuvant therapy over twofold [odds ratio (OR) = 2.20, 95% confidence interval (CI): 1.73-2.80]. Specific complications associated with adjuvant chemotherapy omission were reintubation (OR = 7.79, 95% CI: 3.59-16.87), prolonged ventilation (OR = 5.92, 95% CI: 3.23-10.86), pneumonia (OR = 2.83, 95% CI: 1.63-4.90), sepsis/shock (OR = 2.76, 95% CI: 2.02-3.76), organ space/deep surgical site infection (OR = 2.19, 95% CI: 1.53-3.13), venous thromboembolism (OR = 1.92, 95% CI: 1.08-3.43), and urinary tract infection (OR = 1.61, 95% CI: 1.02-2.54). Serious complications also doubled the likelihood of delaying adjuvant treatment administration (OR = 2.08, 95% CI: 1.42-3.05). Sensitivity analysis in a younger, healthier patient cohort demonstrated similar associations. CONCLUSIONS: Postoperative complications are common following pancreatic surgery and are associated with adjuvant chemotherapy omission and treatment delays.
OBJECTIVE: To assess the impact of postoperative complications on the receipt of adjuvant chemotherapy. BACKGROUND: Randomized trials have demonstrated that adjuvant chemotherapy is associated with improved long-term survival. However, pancreatic surgery is associated with significant morbidity and the degree to which complications limit subsequent treatment options is unknown. METHODS:Patients from the American College of Surgeons National Surgical Quality Improvement Program and the National Cancer Data Base who underwent pancreatic resection for cancer were linked (2006-2009). The associations between complications and adjuvant chemotherapy use or treatment delay (≥ 70 days from surgery) were assessed using multivariable regression methods. RESULTS: From 149 hospitals, 2047 patients underwent resection for stage I-III pancreatic adenocarcinoma of which 23.2% had at least 1 serious complication. Overall adjuvant chemotherapy receipt was 57.7%: 61.8% among patients not experiencing any complication and 43.6% among those who had a serious complication. Serious complications increased the likelihood of not receiving adjuvant therapy over twofold [odds ratio (OR) = 2.20, 95% confidence interval (CI): 1.73-2.80]. Specific complications associated with adjuvant chemotherapy omission were reintubation (OR = 7.79, 95% CI: 3.59-16.87), prolonged ventilation (OR = 5.92, 95% CI: 3.23-10.86), pneumonia (OR = 2.83, 95% CI: 1.63-4.90), sepsis/shock (OR = 2.76, 95% CI: 2.02-3.76), organ space/deep surgical site infection (OR = 2.19, 95% CI: 1.53-3.13), venous thromboembolism (OR = 1.92, 95% CI: 1.08-3.43), and urinary tract infection (OR = 1.61, 95% CI: 1.02-2.54). Serious complications also doubled the likelihood of delaying adjuvant treatment administration (OR = 2.08, 95% CI: 1.42-3.05). Sensitivity analysis in a younger, healthier patient cohort demonstrated similar associations. CONCLUSIONS: Postoperative complications are common following pancreatic surgery and are associated with adjuvant chemotherapy omission and treatment delays.
Authors: Kota Sahara; Anghela Z Paredes; Katiuscha Merath; Diamantis I Tsilimigras; Fabio Bagante; Francesca Ratti; Hugo P Marques; Olivier Soubrane; Eliza W Beal; Vincent Lam; George A Poultsides; Irinel Popescu; Sorin Alexandrescu; Guillaume Martel; Workneh Aklile; Alfredo Guglielmi; Tom Hugh; Luca Aldrighetti; Itaru Endo; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2019-04-01 Impact factor: 3.452
Authors: Rebecca K Marcus; Heather A Lillemoe; David C Rice; Gabriel Mena; Brian K Bednarski; Barbra B Speer; Pedro T Ramirez; Javier D Lasala; Neema Navai; Wendell H Williams; Bradford J Kim; Rachel K Voss; Vijaya N Gottumukkala; Thomas A Aloia Journal: Ann Surg Oncol Date: 2019-01-09 Impact factor: 5.344
Authors: Thomas A Aloia; Giuseppe Zimmitti; Claudius Conrad; Vijaya Gottumukalla; Scott Kopetz; Jean-Nicolas Vauthey Journal: J Surg Oncol Date: 2014-05-21 Impact factor: 3.454
Authors: Grace C Lee; Zhi Ven Fong; Cristina R Ferrone; Sarah P Thayer; Andrew L Warshaw; Keith D Lillemoe; Carlos Fernández-del Castillo Journal: J Gastrointest Surg Date: 2014-08-05 Impact factor: 3.452
Authors: Wenchuan Wu; Jin He; John L Cameron; Martin Makary; Kevin Soares; Nita Ahuja; Neda Rezaee; Joseph Herman; Lei Zheng; Daniel Laheru; Michael A Choti; Ralph H Hruban; Timothy M Pawlik; Christopher L Wolfgang; Matthew J Weiss Journal: Ann Surg Oncol Date: 2014-04-26 Impact factor: 5.344
Authors: Olga Kantor; Mark S Talamonti; Susan J Stocker; Chi-Hsiung Wang; David J Winchester; David J Bentrem; Richard A Prinz; Marshall S Baker Journal: J Gastrointest Surg Date: 2016-02 Impact factor: 3.452
Authors: Brent T Xia; David A Habib; Vikrom K Dhar; Nick C Levinsky; Young Kim; Dennis J Hanseman; Jeffrey M Sutton; Gregory C Wilson; Milton Smith; Kyuran Ann Choe; Jeffrey J Sussman; Syed A Ahmad; Daniel E Abbott Journal: Ann Surg Oncol Date: 2016-07-26 Impact factor: 5.344
Authors: Danielle K DePeralta; Takuya Ogami; Jun-Min Zhou; Michael J Schell; Benjamin D Powers; Pamela J Hodul; Mokenge P Malafa; Jason B Fleming Journal: HPB (Oxford) Date: 2019-09-25 Impact factor: 3.647